Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3918-3926

  Dong, Xiaowei ^a   Mattingly, Cynthia A ^a   Tseng, Michael T ^b   Cho, Moo J ^c   Liu, Yang ^c   Adams, Val R ^a   Mumper, Russell J ^c,d  

^a University of Kentucky   (United States)

^b University of Louisville School of Medicine   (United States)

^c University of North Carolina   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CONTROL GROUP; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR RESISTANCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORESCEINS; HUMANS; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65949120534     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2747     Document Type: Article

References (31)

1. Volm M, Mattern J. Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncog 1996; 7: 227-44.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
3. Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer:mature results of a placebo-controlled randomized trial. J Clin Oncol 1994; 12: 1771-7.
4. Rahman A, Husain SR, Siddiqui J, et al. Liposomemediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 1992; 84: 1909-15.
5. Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicinresistant breast cancer. Cancer Chemother Pharmacol 2002; 50: 6-8.
6. Soma CE, Dubernet C, Barratt G, et al. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 1999; 16: 1710-6.
7. Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006; 23: 1574-85.
8. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. Amechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006; 317: 1372-81.
9. Chavanpatil MD, Patil Y, Panyam J. Susceptibility of nanoparticle- encapsulated paclitaxel to P-glycoproteinmediated drug efflux. Int J Pharm 2006; 320: 150-6.
10. Minko T, Kopeckova P, Pozharov V, Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 1998; 54: 223-33.
11. Minko T, Kopeckova P, Kopecek J. Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMAcopolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 2001; 71: 227-37.
12. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-79.
13. Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 2005; 105: 269-78.
14. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99: 259-69.
15. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006; 112: 312-9.
16. Ma P, Dong X, Swadley CS, Gupte A, Leggas M, Ledebur HC, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgpmediated multiple drug resistance in leukemia. J Biomed Nanotechnol. In press 2009.
17. Dong X, Mattingly CA, Tseng, MT, Cho M, Adams VR, Mumper RJ. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm. In press 2009.
18. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997; 208: 151-8.
19. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
20. Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-8.
21. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers:Selective energy depletion. Br J Cancer 2001; 85: 1987-97.
22. Némati F, Dubernet C, de Verdière AC, et al. Some parameters influencing cytotoxicity of free doxorubicin and doxorubiicn-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells:incubation time, number of nanoparticles per cell. Int J Pharm 1994; 102: 55-62.
23. Tomlinson E, Malspeis L. Concomitant adsorption and stability of some anthracycline antibiotics. J Pharm Sci 1982; 71: 1121-5.
24. de Verdière AC, Dubernet C, Némati F, et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles:towards a mechanism of action. Br J Cancer 1997; 76: 198-205.
25. Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003; 92: 1250-61.
26. Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 2003; 91: 75-83.
27. Dong X, Mumper RJ. The metabolism of fatty alcohols in lipid nanoparticles by alcohol dehydrogenase. Drug Dev Ind Pharm 2006; 32: 973-80.
28. Kaasik A, Safiulina D, Zharkovsky A, Veksler V. Regulation of mitochondrial matrix volume. Am J Physiol Cell Physiol 2007; 292: C157-63.
29. Halestrap AP. The regulation of the oxidation of fatty acids and other substrates in rat heart mitochondria by changes in matrix volume induced by osmotic strength, valinomycin and Ca2+. Biochem J 1987; 244: 159-64.
30. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology:new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11: 127-52.
31. Stowe R, Koening DW, Mishra SK, Piersonb DL. Nondestructive and continuous spectrophotometric measurement of cell respiration using a tetrazoliumformazan microemulsion. J Microbiol Methods 1995; 22: 283-92.